Cardiac imaging
"Magnetic resonance imaging" (originally called nuclear magnetic resonance imaging), an imaging methodology based on aligning the spin axis of nuclei within molecules of the object being visualized using both powerful superconducting magnets and radio frequency and detectors. Cardiology uses are growing, especially since MRI differentiates soft tissues better than CT and allows for comprehensive exams including the quantitative assessment of size, morphology, function, and tissue characteristics in one single session. Current implementations for Cardiology uses are sometimes limited by lengthy protocols, claustrophobia and contraindications based on some complex metallic implants (pacemakers, defibrillators, insulin pumps), while artificial valves and coronary stents are generally not problematic. Image quality can be reduced by the continuous movement of heart structures. There is a promising future in cardiac MRI by more efficient scans, increasing availability of scanners and more widespread knowledge about its clinical application.
Molecular imaging
To achieve molecular imaging of disease biomarkers using MRI, targeted MRI contrast agents with high specificity and high relaxivity (sensitivity) are required. To date, many studies have been devoted to developing targeted-MRI contrast agents to achieve molecular imaging by MRI. Commonly, peptides, antibodies, or small ligands, and small protein domains, such as HER-2 affibodies, have been applied to achieve targeting. To enhance the sensitivity of the contrast agents, these targeting moieties are usually linked to high payload MRI contrast agents or MRI contrast agents with high relaxivities. In particular, the recent development of micron-sized particles of iron oxide (MPIO) allowed to reach unprecedented levels of sensitivity to detect proteins expressed by arteries and veins.